Sunho Biologics (HKSE:02898) ROCE %: -15.12% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02898 Sunho Biologics Inc HKSE:02898
11 GF Score
Price HK$6.39
! 1 Warning Sign
View Full Analysis

What is Sunho Biologics ROCE %?

Sunho Biologics HKSE:02898 11 ROCE % is -15.12% as of Jun. 2025. GuruFocus rates HKSE:02898 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sunho Biologics's annualized ROCE % for the quarter that ended in Jun. 2025 was -15.12%.

Sunho Biologics  (HKSE:02898) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sunho Biologics ROCE % Related Terms

Sunho Biologics ROCE % Historical Data

* Premium members only.

The historical data trend for Sunho Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunho Biologics ROCE % Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
ROCE %
-996.58 0.00 -37.91

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROCE % Get a 7-Day Free Trial -2,549.51 0.00 -31.30 -16.22 -15.12
HKSE:02898
11GF Score
Sunho Biologics Inc HKSE:02898
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunho Biologics ROCE % Calculation

Sunho Biologics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-84.395/( ( (317.688 - 424.018) + (598.681 - 47.133) )/ 2 )
=-84.395/( (-106.33+551.548)/ 2 )
=-84.395/222.609
=-37.91 %

Sunho Biologics's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=-81.702/( ( (598.681 - 47.133) + (609.798 - 80.968) )/ 2 )
=-81.702/( ( 551.548 + 528.83 )/ 2 )
=-81.702/540.189
=-15.12 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -15.12% mean?
Sunho Biologics (HKSE:02898) has a ROCE % of -15.12% as of Jun. 2025.
Is Sunho Biologics' ROCE % too high?
Sunho Biologics' current ROCE % is -15.12%. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' ROCE % compare to VRTX and REGN?
Sunho Biologics' ROCE % of -15.12% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sunho Biologics's current ROCE % is -15.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current ROCE % of -15.12%. The current ROCE % is -15.12%. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current ROCE % is -15.12% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunho Biologics Business Description

Address No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score

Get the complete analysis for HKSE:02898

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.39
Price